カテゴリー： 世界, 医療/バイオ, LP Information

世界の非ベンゾジアゼピン系薬剤市場予測 2023年-2029年

【英語タイトル】Global Non-Benzodiazepines Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC06961）・商品コード：LP23DC06961
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：111
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥549,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥823,500見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,098,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の非ベンゾジアゼピン系薬剤市場」は、過去の販売実績から2022年の世界の非ベンゾジアゼピン系薬剤の総販売量を検討し、2023年から2029年の予測される非ベンゾジアゼピン系薬剤の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の非ベンゾジアゼピン系薬剤の市場規模を掲載し、XXX百万米ドル規模の世界の非ベンゾジアゼピン系薬剤市場の詳細な分析を提供します。本インサイトレポートは、世界の非ベンゾジアゼピン系薬剤業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の非ベンゾジアゼピン系薬剤市場における各社の独自のポジションをより深く理解するために、非ベンゾジアゼピン系薬剤製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の非ベンゾジアゼピン系薬剤市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。非ベンゾジアゼピン系薬剤の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。非ベンゾジアゼピン系薬剤の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。非ベンゾジアゼピン系薬剤のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

非ベンゾジアゼピン系薬剤の世界主要メーカーとしては、Pfizer、 Teva Pharmaceuticals、 Torrent Pharma、 Accord Healthcare、 Akorn、 Apotex、 Fresenius Kabi、 Hikma、 Mylan、 Par Pharmaceuticals、 Sandoz、 Sun Pharma、 WG Critical Care、 Athenex、 Chenxin Pharmaceutical、 Huatai Chenguang Pharmaceuticalなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の非ベンゾジアゼピン系薬剤市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では非ベンゾジアゼピン系薬剤市場をセグメンテーションし、種類別 (デクスメデトミジン、ゾルピデム、エスゾピクロン、ゾピクロン、他)、用途別 (病院、診療所、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：デクスメデトミジン、ゾルピデム、エスゾピクロン、ゾピクロン、他

・用途別区分：病院、診療所、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の非ベンゾジアゼピン系薬剤市場の10年間の市場状況・展望は？
・世界および地域別に見た非ベンゾジアゼピン系薬剤市場成長の要因は何か？
・非ベンゾジアゼピン系薬剤の市場機会はエンドマーケットの規模によってどのように変化するのか？
・非ベンゾジアゼピン系薬剤のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：非ベンゾジアゼピン系薬剤の年間販売量2018-2029、地域別現状・将来分析
・非ベンゾジアゼピン系薬剤の種類別セグメント：デクスメデトミジン、ゾルピデム、エスゾピクロン、ゾピクロン、他
・非ベンゾジアゼピン系薬剤の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・非ベンゾジアゼピン系薬剤の用途別セグメント：病院、診療所、その他
・非ベンゾジアゼピン系薬剤の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の非ベンゾジアゼピン系薬剤市場
・企業別のグローバル非ベンゾジアゼピン系薬剤市場データ：2018-2023年の年間販売量、市場シェア
・企業別の非ベンゾジアゼピン系薬剤の年間売上：2018-2023年の売上、市場シェア
・企業別の非ベンゾジアゼピン系薬剤販売価格
・主要企業の非ベンゾジアゼピン系薬剤生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

非ベンゾジアゼピン系薬剤の地域別レビュー
・地域別の非ベンゾジアゼピン系薬剤市場規模2018-2023：年間販売量、売上
・主要国別の非ベンゾジアゼピン系薬剤市場規模2018-2023：年間販売量、売上
・南北アメリカの非ベンゾジアゼピン系薬剤販売の成長
・アジア太平洋の非ベンゾジアゼピン系薬剤販売の成長
・ヨーロッパの非ベンゾジアゼピン系薬剤販売の成長
・中東・アフリカの非ベンゾジアゼピン系薬剤販売の成長

南北アメリカ市場
・南北アメリカの国別の非ベンゾジアゼピン系薬剤販売量、売上（2018-2023）
・南北アメリカの非ベンゾジアゼピン系薬剤の種類別販売量
・南北アメリカの非ベンゾジアゼピン系薬剤の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の非ベンゾジアゼピン系薬剤販売量、売上（2018-2023）
・アジア太平洋の非ベンゾジアゼピン系薬剤の種類別販売量
・アジア太平洋の非ベンゾジアゼピン系薬剤の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の非ベンゾジアゼピン系薬剤販売量、売上（2018-2023）
・ヨーロッパの非ベンゾジアゼピン系薬剤の種類別販売量
・ヨーロッパの非ベンゾジアゼピン系薬剤の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の非ベンゾジアゼピン系薬剤販売量、売上（2018-2023）
・中東・アフリカの非ベンゾジアゼピン系薬剤の種類別販売量
・中東・アフリカの非ベンゾジアゼピン系薬剤の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・非ベンゾジアゼピン系薬剤の製造コスト構造分析
・非ベンゾジアゼピン系薬剤の製造プロセス分析
・非ベンゾジアゼピン系薬剤の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・非ベンゾジアゼピン系薬剤の主要なグローバル販売業者
・非ベンゾジアゼピン系薬剤の主要なグローバル顧客

地域別の非ベンゾジアゼピン系薬剤市場予測レビュー
・地域別の非ベンゾジアゼピン系薬剤市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・非ベンゾジアゼピン系薬剤の種類別市場規模予測
・非ベンゾジアゼピン系薬剤の用途別市場規模予測

主要企業分析
Pfizer、 Teva Pharmaceuticals、 Torrent Pharma、 Accord Healthcare、 Akorn、 Apotex、 Fresenius Kabi、 Hikma、 Mylan、 Par Pharmaceuticals、 Sandoz、 Sun Pharma、 WG Critical Care、 Athenex、 Chenxin Pharmaceutical、 Huatai Chenguang Pharmaceutical
・企業情報
・非ベンゾジアゼピン系薬剤製品
・非ベンゾジアゼピン系薬剤販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Non-Benzodiazepines market size is projected to grow from US$ 635.9 million in 2022 to US$ 1445.6 million in 2029; it is expected to grow at a CAGR of 12.4% from 2023 to 2029.
United States market for Non-Benzodiazepines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Non-Benzodiazepines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Non-Benzodiazepines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Non-Benzodiazepines players cover Pfizer, Teva Pharmaceuticals, Torrent Pharma, Accord Healthcare, Akorn, Apotex, Fresenius Kabi, Hikma and Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Non-benzodiazepines are a relatively new class of hypnotics
LPI (LP Information)’ newest research report, the “Non-Benzodiazepines Industry Forecast” looks at past sales and reviews total world Non-Benzodiazepines sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-Benzodiazepines sales for 2023 through 2029. With Non-Benzodiazepines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Benzodiazepines industry.
This Insight Report provides a comprehensive analysis of the global Non-Benzodiazepines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-Benzodiazepines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Benzodiazepines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Benzodiazepines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Benzodiazepines.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Benzodiazepines market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Dexmedetomidine
Zolpidem
Eszopiclone
Zopiclone
other
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Pfizer
Teva Pharmaceuticals
Torrent Pharma
Accord Healthcare
Akorn
Apotex
Fresenius Kabi
Hikma
Mylan
Par Pharmaceuticals
Sandoz
Sun Pharma
WG Critical Care
Athenex
Chenxin Pharmaceutical
Huatai Chenguang Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Non-Benzodiazepines market?
What factors are driving Non-Benzodiazepines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-Benzodiazepines market opportunities vary by end market size?
How does Non-Benzodiazepines break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Non-Benzodiazepines Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Non-Benzodiazepines by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Non-Benzodiazepines by Country/Region, 2018, 2022 & 2029
2.2 Non-Benzodiazepines Segment by Type
2.2.1 Dexmedetomidine
2.2.2 Zolpidem
2.2.3 Eszopiclone
2.2.4 Zopiclone
2.2.5 other
2.3 Non-Benzodiazepines Sales by Type
2.3.1 Global Non-Benzodiazepines Sales Market Share by Type (2018-2023)
2.3.2 Global Non-Benzodiazepines Revenue and Market Share by Type (2018-2023)
2.3.3 Global Non-Benzodiazepines Sale Price by Type (2018-2023)
2.4 Non-Benzodiazepines Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Non-Benzodiazepines Sales by Application
2.5.1 Global Non-Benzodiazepines Sale Market Share by Application (2018-2023)
2.5.2 Global Non-Benzodiazepines Revenue and Market Share by Application (2018-2023)
2.5.3 Global Non-Benzodiazepines Sale Price by Application (2018-2023)
3 Global Non-Benzodiazepines by Company
3.1 Global Non-Benzodiazepines Breakdown Data by Company
3.1.1 Global Non-Benzodiazepines Annual Sales by Company (2018-2023)
3.1.2 Global Non-Benzodiazepines Sales Market Share by Company (2018-2023)
3.2 Global Non-Benzodiazepines Annual Revenue by Company (2018-2023)
3.2.1 Global Non-Benzodiazepines Revenue by Company (2018-2023)
3.2.2 Global Non-Benzodiazepines Revenue Market Share by Company (2018-2023)
3.3 Global Non-Benzodiazepines Sale Price by Company
3.4 Key Manufacturers Non-Benzodiazepines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-Benzodiazepines Product Location Distribution
3.4.2 Players Non-Benzodiazepines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Non-Benzodiazepines by Geographic Region
4.1 World Historic Non-Benzodiazepines Market Size by Geographic Region (2018-2023)
4.1.1 Global Non-Benzodiazepines Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Non-Benzodiazepines Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Non-Benzodiazepines Market Size by Country/Region (2018-2023)
4.2.1 Global Non-Benzodiazepines Annual Sales by Country/Region (2018-2023)
4.2.2 Global Non-Benzodiazepines Annual Revenue by Country/Region (2018-2023)
4.3 Americas Non-Benzodiazepines Sales Growth
4.4 APAC Non-Benzodiazepines Sales Growth
4.5 Europe Non-Benzodiazepines Sales Growth
4.6 Middle East & Africa Non-Benzodiazepines Sales Growth
5 Americas
5.1 Americas Non-Benzodiazepines Sales by Country
5.1.1 Americas Non-Benzodiazepines Sales by Country (2018-2023)
5.1.2 Americas Non-Benzodiazepines Revenue by Country (2018-2023)
5.2 Americas Non-Benzodiazepines Sales by Type
5.3 Americas Non-Benzodiazepines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Benzodiazepines Sales by Region
6.1.1 APAC Non-Benzodiazepines Sales by Region (2018-2023)
6.1.2 APAC Non-Benzodiazepines Revenue by Region (2018-2023)
6.2 APAC Non-Benzodiazepines Sales by Type
6.3 APAC Non-Benzodiazepines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Non-Benzodiazepines by Country
7.1.1 Europe Non-Benzodiazepines Sales by Country (2018-2023)
7.1.2 Europe Non-Benzodiazepines Revenue by Country (2018-2023)
7.2 Europe Non-Benzodiazepines Sales by Type
7.3 Europe Non-Benzodiazepines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Non-Benzodiazepines by Country
8.1.1 Middle East & Africa Non-Benzodiazepines Sales by Country (2018-2023)
8.1.2 Middle East & Africa Non-Benzodiazepines Revenue by Country (2018-2023)
8.2 Middle East & Africa Non-Benzodiazepines Sales by Type
8.3 Middle East & Africa Non-Benzodiazepines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-Benzodiazepines
10.3 Manufacturing Process Analysis of Non-Benzodiazepines
10.4 Industry Chain Structure of Non-Benzodiazepines
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-Benzodiazepines Distributors
11.3 Non-Benzodiazepines Customer
12 World Forecast Review for Non-Benzodiazepines by Geographic Region
12.1 Global Non-Benzodiazepines Market Size Forecast by Region
12.1.1 Global Non-Benzodiazepines Forecast by Region (2024-2029)
12.1.2 Global Non-Benzodiazepines Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non-Benzodiazepines Forecast by Type
12.7 Global Non-Benzodiazepines Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Non-Benzodiazepines Product Portfolios and Specifications
13.1.3 Pfizer Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Teva Pharmaceuticals
13.2.1 Teva Pharmaceuticals Company Information
13.2.2 Teva Pharmaceuticals Non-Benzodiazepines Product Portfolios and Specifications
13.2.3 Teva Pharmaceuticals Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Teva Pharmaceuticals Main Business Overview
13.2.5 Teva Pharmaceuticals Latest Developments
13.3 Torrent Pharma
13.3.1 Torrent Pharma Company Information
13.3.2 Torrent Pharma Non-Benzodiazepines Product Portfolios and Specifications
13.3.3 Torrent Pharma Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Torrent Pharma Main Business Overview
13.3.5 Torrent Pharma Latest Developments
13.4 Accord Healthcare
13.4.1 Accord Healthcare Company Information
13.4.2 Accord Healthcare Non-Benzodiazepines Product Portfolios and Specifications
13.4.3 Accord Healthcare Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Accord Healthcare Main Business Overview
13.4.5 Accord Healthcare Latest Developments
13.5 Akorn
13.5.1 Akorn Company Information
13.5.2 Akorn Non-Benzodiazepines Product Portfolios and Specifications
13.5.3 Akorn Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Akorn Main Business Overview
13.5.5 Akorn Latest Developments
13.6 Apotex
13.6.1 Apotex Company Information
13.6.2 Apotex Non-Benzodiazepines Product Portfolios and Specifications
13.6.3 Apotex Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Apotex Main Business Overview
13.6.5 Apotex Latest Developments
13.7 Fresenius Kabi
13.7.1 Fresenius Kabi Company Information
13.7.2 Fresenius Kabi Non-Benzodiazepines Product Portfolios and Specifications
13.7.3 Fresenius Kabi Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Fresenius Kabi Main Business Overview
13.7.5 Fresenius Kabi Latest Developments
13.8 Hikma
13.8.1 Hikma Company Information
13.8.2 Hikma Non-Benzodiazepines Product Portfolios and Specifications
13.8.3 Hikma Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Hikma Main Business Overview
13.8.5 Hikma Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan Non-Benzodiazepines Product Portfolios and Specifications
13.9.3 Mylan Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Par Pharmaceuticals
13.10.1 Par Pharmaceuticals Company Information
13.10.2 Par Pharmaceuticals Non-Benzodiazepines Product Portfolios and Specifications
13.10.3 Par Pharmaceuticals Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Par Pharmaceuticals Main Business Overview
13.10.5 Par Pharmaceuticals Latest Developments
13.11 Sandoz
13.11.1 Sandoz Company Information
13.11.2 Sandoz Non-Benzodiazepines Product Portfolios and Specifications
13.11.3 Sandoz Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Sandoz Main Business Overview
13.11.5 Sandoz Latest Developments
13.12 Sun Pharma
13.12.1 Sun Pharma Company Information
13.12.2 Sun Pharma Non-Benzodiazepines Product Portfolios and Specifications
13.12.3 Sun Pharma Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sun Pharma Main Business Overview
13.12.5 Sun Pharma Latest Developments
13.13 WG Critical Care
13.13.1 WG Critical Care Company Information
13.13.2 WG Critical Care Non-Benzodiazepines Product Portfolios and Specifications
13.13.3 WG Critical Care Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 WG Critical Care Main Business Overview
13.13.5 WG Critical Care Latest Developments
13.14 Athenex
13.14.1 Athenex Company Information
13.14.2 Athenex Non-Benzodiazepines Product Portfolios and Specifications
13.14.3 Athenex Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Athenex Main Business Overview
13.14.5 Athenex Latest Developments
13.15 Chenxin Pharmaceutical
13.15.1 Chenxin Pharmaceutical Company Information
13.15.2 Chenxin Pharmaceutical Non-Benzodiazepines Product Portfolios and Specifications
13.15.3 Chenxin Pharmaceutical Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Chenxin Pharmaceutical Main Business Overview
13.15.5 Chenxin Pharmaceutical Latest Developments
13.16 Huatai Chenguang Pharmaceutical
13.16.1 Huatai Chenguang Pharmaceutical Company Information
13.16.2 Huatai Chenguang Pharmaceutical Non-Benzodiazepines Product Portfolios and Specifications
13.16.3 Huatai Chenguang Pharmaceutical Non-Benzodiazepines Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Huatai Chenguang Pharmaceutical Main Business Overview
13.16.5 Huatai Chenguang Pharmaceutical Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Non-Benzodiazepines Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Non-Benzodiazepines Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Dexmedetomidine
Table 4. Major Players of Zolpidem
Table 5. Major Players of Eszopiclone
Table 6. Major Players of Zopiclone
Table 7. Major Players of other
Table 8. Global Non-Benzodiazepines Sales by Type (2018-2023) & (K Units)
Table 9. Global Non-Benzodiazepines Sales Market Share by Type (2018-2023)
Table 10. Global Non-Benzodiazepines Revenue by Type (2018-2023) & ($ million)
Table 11. Global Non-Benzodiazepines Revenue Market Share by Type (2018-2023)
Table 12. Global Non-Benzodiazepines Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global Non-Benzodiazepines Sales by Application (2018-2023) & (K Units)
Table 14. Global Non-Benzodiazepines Sales Market Share by Application (2018-2023)
Table 15. Global Non-Benzodiazepines Revenue by Application (2018-2023)
Table 16. Global Non-Benzodiazepines Revenue Market Share by Application (2018-2023)
Table 17. Global Non-Benzodiazepines Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global Non-Benzodiazepines Sales by Company (2018-2023) & (K Units)
Table 19. Global Non-Benzodiazepines Sales Market Share by Company (2018-2023)
Table 20. Global Non-Benzodiazepines Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Non-Benzodiazepines Revenue Market Share by Company (2018-2023)
Table 22. Global Non-Benzodiazepines Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers Non-Benzodiazepines Producing Area Distribution and Sales Area
Table 24. Players Non-Benzodiazepines Products Offered
Table 25. Non-Benzodiazepines Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Non-Benzodiazepines Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Non-Benzodiazepines Sales Market Share Geographic Region (2018-2023)
Table 30. Global Non-Benzodiazepines Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Non-Benzodiazepines Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Non-Benzodiazepines Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Non-Benzodiazepines Sales Market Share by Country/Region (2018-2023)
Table 34. Global Non-Benzodiazepines Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Non-Benzodiazepines Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Non-Benzodiazepines Sales by Country (2018-2023) & (K Units)
Table 37. Americas Non-Benzodiazepines Sales Market Share by Country (2018-2023)
Table 38. Americas Non-Benzodiazepines Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Non-Benzodiazepines Revenue Market Share by Country (2018-2023)
Table 40. Americas Non-Benzodiazepines Sales by Type (2018-2023) & (K Units)
Table 41. Americas Non-Benzodiazepines Sales by Application (2018-2023) & (K Units)
Table 42. APAC Non-Benzodiazepines Sales by Region (2018-2023) & (K Units)
Table 43. APAC Non-Benzodiazepines Sales Market Share by Region (2018-2023)
Table 44. APAC Non-Benzodiazepines Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Non-Benzodiazepines Revenue Market Share by Region (2018-2023)
Table 46. APAC Non-Benzodiazepines Sales by Type (2018-2023) & (K Units)
Table 47. APAC Non-Benzodiazepines Sales by Application (2018-2023) & (K Units)
Table 48. Europe Non-Benzodiazepines Sales by Country (2018-2023) & (K Units)
Table 49. Europe Non-Benzodiazepines Sales Market Share by Country (2018-2023)
Table 50. Europe Non-Benzodiazepines Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Non-Benzodiazepines Revenue Market Share by Country (2018-2023)
Table 52. Europe Non-Benzodiazepines Sales by Type (2018-2023) & (K Units)
Table 53. Europe Non-Benzodiazepines Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Non-Benzodiazepines Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Non-Benzodiazepines Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Non-Benzodiazepines Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Non-Benzodiazepines Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Non-Benzodiazepines Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Non-Benzodiazepines Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Non-Benzodiazepines
Table 61. Key Market Challenges & Risks of Non-Benzodiazepines
Table 62. Key Industry Trends of Non-Benzodiazepines
Table 63. Non-Benzodiazepines Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Non-Benzodiazepines Distributors List
Table 66. Non-Benzodiazepines Customer List
Table 67. Global Non-Benzodiazepines Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Non-Benzodiazepines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Non-Benzodiazepines Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Non-Benzodiazepines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Non-Benzodiazepines Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Non-Benzodiazepines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Non-Benzodiazepines Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Non-Benzodiazepines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Non-Benzodiazepines Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Non-Benzodiazepines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Non-Benzodiazepines Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Non-Benzodiazepines Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Non-Benzodiazepines Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Non-Benzodiazepines Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Pfizer Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 82. Pfizer Non-Benzodiazepines Product Portfolios and Specifications
Table 83. Pfizer Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. Pfizer Main Business
Table 85. Pfizer Latest Developments
Table 86. Teva Pharmaceuticals Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 87. Teva Pharmaceuticals Non-Benzodiazepines Product Portfolios and Specifications
Table 88. Teva Pharmaceuticals Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Teva Pharmaceuticals Main Business
Table 90. Teva Pharmaceuticals Latest Developments
Table 91. Torrent Pharma Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 92. Torrent Pharma Non-Benzodiazepines Product Portfolios and Specifications
Table 93. Torrent Pharma Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Torrent Pharma Main Business
Table 95. Torrent Pharma Latest Developments
Table 96. Accord Healthcare Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 97. Accord Healthcare Non-Benzodiazepines Product Portfolios and Specifications
Table 98. Accord Healthcare Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. Accord Healthcare Main Business
Table 100. Accord Healthcare Latest Developments
Table 101. Akorn Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 102. Akorn Non-Benzodiazepines Product Portfolios and Specifications
Table 103. Akorn Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Akorn Main Business
Table 105. Akorn Latest Developments
Table 106. Apotex Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 107. Apotex Non-Benzodiazepines Product Portfolios and Specifications
Table 108. Apotex Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Apotex Main Business
Table 110. Apotex Latest Developments
Table 111. Fresenius Kabi Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 112. Fresenius Kabi Non-Benzodiazepines Product Portfolios and Specifications
Table 113. Fresenius Kabi Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 114. Fresenius Kabi Main Business
Table 115. Fresenius Kabi Latest Developments
Table 116. Hikma Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 117. Hikma Non-Benzodiazepines Product Portfolios and Specifications
Table 118. Hikma Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 119. Hikma Main Business
Table 120. Hikma Latest Developments
Table 121. Mylan Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 122. Mylan Non-Benzodiazepines Product Portfolios and Specifications
Table 123. Mylan Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 124. Mylan Main Business
Table 125. Mylan Latest Developments
Table 126. Par Pharmaceuticals Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 127. Par Pharmaceuticals Non-Benzodiazepines Product Portfolios and Specifications
Table 128. Par Pharmaceuticals Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 129. Par Pharmaceuticals Main Business
Table 130. Par Pharmaceuticals Latest Developments
Table 131. Sandoz Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 132. Sandoz Non-Benzodiazepines Product Portfolios and Specifications
Table 133. Sandoz Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 134. Sandoz Main Business
Table 135. Sandoz Latest Developments
Table 136. Sun Pharma Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 137. Sun Pharma Non-Benzodiazepines Product Portfolios and Specifications
Table 138. Sun Pharma Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 139. Sun Pharma Main Business
Table 140. Sun Pharma Latest Developments
Table 141. WG Critical Care Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 142. WG Critical Care Non-Benzodiazepines Product Portfolios and Specifications
Table 143. WG Critical Care Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 144. WG Critical Care Main Business
Table 145. WG Critical Care Latest Developments
Table 146. Athenex Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 147. Athenex Non-Benzodiazepines Product Portfolios and Specifications
Table 148. Athenex Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 149. Athenex Main Business
Table 150. Athenex Latest Developments
Table 151. Chenxin Pharmaceutical Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 152. Chenxin Pharmaceutical Non-Benzodiazepines Product Portfolios and Specifications
Table 153. Chenxin Pharmaceutical Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 154. Chenxin Pharmaceutical Main Business
Table 155. Chenxin Pharmaceutical Latest Developments
Table 156. Huatai Chenguang Pharmaceutical Basic Information, Non-Benzodiazepines Manufacturing Base, Sales Area and Its Competitors
Table 157. Huatai Chenguang Pharmaceutical Non-Benzodiazepines Product Portfolios and Specifications
Table 158. Huatai Chenguang Pharmaceutical Non-Benzodiazepines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 159. Huatai Chenguang Pharmaceutical Main Business
Table 160. Huatai Chenguang Pharmaceutical Latest Developments
List of Figures
Figure 1. Picture of Non-Benzodiazepines
Figure 2. Non-Benzodiazepines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-Benzodiazepines Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Non-Benzodiazepines Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Non-Benzodiazepines Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Dexmedetomidine
Figure 10. Product Picture of Zolpidem
Figure 11. Product Picture of Eszopiclone
Figure 12. Product Picture of Zopiclone
Figure 13. Product Picture of other
Figure 14. Global Non-Benzodiazepines Sales Market Share by Type in 2022
Figure 15. Global Non-Benzodiazepines Revenue Market Share by Type (2018-2023)
Figure 16. Non-Benzodiazepines Consumed in Hospital
Figure 17. Global Non-Benzodiazepines Market: Hospital (2018-2023) & (K Units)
Figure 18. Non-Benzodiazepines Consumed in Clinic
Figure 19. Global Non-Benzodiazepines Market: Clinic (2018-2023) & (K Units)
Figure 20. Non-Benzodiazepines Consumed in Other
Figure 21. Global Non-Benzodiazepines Market: Other (2018-2023) & (K Units)
Figure 22. Global Non-Benzodiazepines Sales Market Share by Application (2022)
Figure 23. Global Non-Benzodiazepines Revenue Market Share by Application in 2022
Figure 24. Non-Benzodiazepines Sales Market by Company in 2022 (K Units)
Figure 25. Global Non-Benzodiazepines Sales Market Share by Company in 2022
Figure 26. Non-Benzodiazepines Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Non-Benzodiazepines Revenue Market Share by Company in 2022
Figure 28. Global Non-Benzodiazepines Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Non-Benzodiazepines Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Non-Benzodiazepines Sales 2018-2023 (K Units)
Figure 31. Americas Non-Benzodiazepines Revenue 2018-2023 ($ Millions)
Figure 32. APAC Non-Benzodiazepines Sales 2018-2023 (K Units)
Figure 33. APAC Non-Benzodiazepines Revenue 2018-2023 ($ Millions)
Figure 34. Europe Non-Benzodiazepines Sales 2018-2023 (K Units)
Figure 35. Europe Non-Benzodiazepines Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Non-Benzodiazepines Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Non-Benzodiazepines Revenue 2018-2023 ($ Millions)
Figure 38. Americas Non-Benzodiazepines Sales Market Share by Country in 2022
Figure 39. Americas Non-Benzodiazepines Revenue Market Share by Country in 2022
Figure 40. Americas Non-Benzodiazepines Sales Market Share by Type (2018-2023)
Figure 41. Americas Non-Benzodiazepines Sales Market Share by Application (2018-2023)
Figure 42. United States Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Non-Benzodiazepines Sales Market Share by Region in 2022
Figure 47. APAC Non-Benzodiazepines Revenue Market Share by Regions in 2022
Figure 48. APAC Non-Benzodiazepines Sales Market Share by Type (2018-2023)
Figure 49. APAC Non-Benzodiazepines Sales Market Share by Application (2018-2023)
Figure 50. China Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Non-Benzodiazepines Sales Market Share by Country in 2022
Figure 58. Europe Non-Benzodiazepines Revenue Market Share by Country in 2022
Figure 59. Europe Non-Benzodiazepines Sales Market Share by Type (2018-2023)
Figure 60. Europe Non-Benzodiazepines Sales Market Share by Application (2018-2023)
Figure 61. Germany Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Non-Benzodiazepines Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Non-Benzodiazepines Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Non-Benzodiazepines Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Non-Benzodiazepines Sales Market Share by Application (2018-2023)
Figure 70. Egypt Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Non-Benzodiazepines Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Non-Benzodiazepines in 2022
Figure 76. Manufacturing Process Analysis of Non-Benzodiazepines
Figure 77. Industry Chain Structure of Non-Benzodiazepines
Figure 78. Channels of Distribution
Figure 79. Global Non-Benzodiazepines Sales Market Forecast by Region (2024-2029)
Figure 80. Global Non-Benzodiazepines Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Non-Benzodiazepines Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Non-Benzodiazepines Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Non-Benzodiazepines Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Non-Benzodiazepines Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の非ベンゾジアゼピン系薬剤市場予測 2023年-2029年] (コード：LP23DC06961)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の非ベンゾジアゼピン系薬剤市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のPVC手動蘇生器市場予測 2023年-2029年
  • 世界のマルチビタミンミネラル市場予測 2023年-2029年
  • 世界の義肢装具市場予測 2023年-2029年
  • 世界のワイヤレス外科用ヘッドライト市場予測 2023年-2029年
  • 世界のワイヤレスECGモニター市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆